# Tom Schoenherr

> Tom Schoenherr is CEO of Diagnostics at Tempus AI, the publicly traded precision-medicine company. He previously ran Ambry Genetics as CEO from 2021 to 2025, steering it through a definitive agreement to be acquired by Tempus. He has spent more than 25 years inside molecular diagnostics, with prior leadership stints at Counsyl, Quest Diagnostics, Siemens Healthcare, Abbott Diagnostics, and Omada Health.

- **Role:** CEO of Diagnostics at Tempus AI
- **Organizations:** Tempus AI, Ambry Genetics, Counsyl, Omada Health, Quest Diagnostics, Siemens Healthcare, Abbott Diagnostics
- **Nationality:** American
- **Education:** B.S., Michigan State University, Executive Business Development Program, University of Notre Dame
- **Known for:** Led Ambry Genetics through its acquisition by Tempus AI, Oversaw launch of ExomeReveal at Ambry Genetics, Drove record growth at Ambry during a turbulent period for clinical genomics

## Career timeline

- **2017** — Joined Ambry Genetics as Chief Commercial Officer
- **2021** — Promoted to CEO of Ambry Genetics
- **2025** — Ambry Genetics acquired by Tempus AI; appointed CEO of Diagnostics at Tempus
- **2026** — Continues to lead Tempus Diagnostics through public-company growth phase

## Achievements

- Led Ambry Genetics through its acquisition by Tempus AI
- Oversaw launch of ExomeReveal at Ambry Genetics
- Drove record growth at Ambry during a turbulent period for clinical genomics
- Built commercial functions from scratch at multiple diagnostics companies

## Latest updates

- **2025** — Appointed CEO of Diagnostics at Tempus AI following Ambry acquisition
- **2026-05** — Tempus AI announces inaugural Investor Day for May 29, 2026

## Links

- Website: https://www.tempus.com/team_members/tom-schoenherr/
- LinkedIn: https://www.linkedin.com/in/tomschoenherr1/

---

Profile page: https://yespress.io/tom-schoenherr
Published by YesPress — https://yespress.io
Last updated: 2026-05-30